Generex Biotechnology Partner Olaregen Therapeutix Inc. Signs Manufacturing Agreements for Excellagen® Wound Healing Collagen Matrix Collagen Solutions & Berkshire Sterile Manufacturing to Supply ...
WORCESTER, Mass., Sept. 1, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced ...
Generex receives $2 million payment from Chinese partners to provide research results, data, and necessary documents to support an IND submission to the Chinese National Medical Products ...
WORCESTER, Mass., Aug. 27, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com ), the leader in drug delivery for metabolic diseases through the inner lining of ...
Ii-Key-SARS-CoV-2 vaccine generates vaccine-specific antibodies and T cell responses in a transgenic mouse model The Ii-Key vaccine elicits both CD4+ T Helper cell (Th1) and CD8+ responses that are ...
MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the company has relaunched its corporate website to provide details on a revamped ...
Generex’s Ii-Key peptide vaccines for infectious disease and cancer have been studied in human clinical trials involving over 300 subjects in Phase I and Phase II ...
Filing of up-list application to Nasdaq Details on 1:1 Shareholder stock dividend Recording and transcript of shareholders conference call available at www.generex.com “Lastly, it is important to note ...
SIA "Generex Biotechnology BALTIC" to Focus On Registration Efforts in the Baltic Region and Europe for All Company Developments and Products WORCESTER, Mass., Sep 2 ...
After three years as a financial executive, Anthony Crisci is returning to the in-house legal world and taking on new responsibilities at Generex Biotechnology Corp. Crisci is the new general manager, ...
Generex to receive $10M in common stock, a warrant, & $1M in R&D funding WORCESTER, Mass. and TORONTO, April 23, 2015 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) ...
Company Receives Independent Appraisal of Breast Cancer Vaccine in Excess of $300 Million at Its Current Stage of Development WORCESTER, Mass., Jan. 25, 2011 /PRNewswire/ -- Generex Biotechnology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results